Delix Therapeutics is a neuroscience company developing novel therapeutics to address brain health challenges. The company aims to push the boundaries of neuroscience and create new types of medicine for brain health.

Delix Therapeutics

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Talent Resources Ventures

Comerica - Technology & Life Sciences

National Institute on Drug Abuse (NIDA)

RA Capital Management

WPSS Investments

Apeiron Holdings Limited

Bail Capital

Vertical Venture Partners

Casa Verde Capital

Negev Capital

Ocama Partners

OMX Ventures

Meet Andrew Felts, PhD, Principal Scientist, Medicinal Chemistry at Delix Therapeutics! Andrew loves to contribute to the innovative research Delix is conducting in neuroplasticity and the role it plays in various #CNS disorders of enormous unmet need. We value his expertise and dedication to cutting-edge science as we continue to push boundaries to develop groundbreaking therapeutics for #neuropsychiatric conditions.

Exciting development: Delix Therapeutics founder and Chief Innovation Officer, David E. Olson, along with Christina Kim and the team at UC Davis Institute for Psychedelics and Neurotherapeutics, have introduced a cutting-edge approach for tracking calcium signaling in #neurons— dubbed CaST—and published the discovery in Nature Portfolio. #NatureMethods

Unlike traditional sensors that are limited by transient readouts or invasive methods, CaST tags cells with elevated Ca2+ quickly and reversibly with high precision. This breakthrough enables researchers to measure neuronal activity in mice with incredible detail.

The team from University of California, Davis is leveraging this novel system to explore the effects of #psilocybin on #PFC neurons and correlate activity with a behavioral readout, namely the #Head Twitch Response. Learn more here: https://lnkd.in/g2Sv4d-W #neuroscience #innovation #brainresearch

An amazing time was had by all at the Delix Summer Porchfest 2024, featuring our very own “house band,” the Neuroplastic Fantastic! It’s always important to come together, relax, and enjoy some well-deserved time with our team and families.

A big thank you to all Delix Therapeutics team members who made it such a memorable day! We wish everyone a great rest of the summer filled with memorable moments with your own families and friends.

Today we observe #WorldBrainDay, dedicated to promoting #brainhealth and raising awareness about neurological disorders. With over 3 billion people affected by #neurological conditions worldwide, advancing brain research is crucial for improving cognitive function, reducing the risk of neurological issues, and enhancing overall #mentalhealth.

At Delix Therapeutics, we're leveraging the brain's natural capacity for targeted restoration and repair. Our innovative compounds hold the potential to revolutionize the treatment landscape for various #CNS conditions. Learn more about our innovative #neuroplastogens here: https://lnkd.in/dqnHGFyw.

Meet Rajiv Agrawal, Associate Director, Pharmacology at Delix Therapeutics! Rajiv pushes the boundaries of #CNS drug discovery by tackling new challenges and contributing to essential research projects. His expertise is invaluable as we continue to strive to develop innovative therapeutics for patients with #neuropsychiatric conditions.

We’re excited to welcome Sydney DeCaro to #TeamDelix as a Clinical Trial Associate.

Sydney shared her reasons for joining #TeamDelix:

“I am very excited to join the Delix Therapeutics team! Having worked on an intravenous ketamine trial for severe depression, I witnessed firsthand the remarkable effect of plastogens in those suffering from neuropsychiatric disorders. However, I also recognized the challenges related to accessibility, scalability, and the substantial resources and time required for administration and monitoring. Delix’s lead compound has the potential to overcome these challenges and reach a much broader patient population, which fueled my interest in joining the team. I am thrilled to be joining the innovative and driven team at Delix!”

We’re excited to have Sydney on board and know her expertise will be a significant asset to the team.

On #NationalPTSDAwarenessDay, we raise awareness of the daily struggles faced by millions impacted by post-traumatic stress disorder. 

Delix Therapeutics recognizes the profound impact PTSD has on patients and their loved ones, which is why our research is at the forefront of understanding the neurological mechanisms underlying this disease. Through our novel #neuroplastogen development platform, we're committed to pursuing transformative treatment options for patients with debilitating #neuropsychiatric disorders.

Learn more about our approach here: https://lnkd.in/eCRnJMv5.

Scientific American recently published a piece highlighting the potential of next-generation psychedelics as medicines, especially non-hallucinogenic compounds like Delix Therapeutics's #neuroplastogens. The article features our CSO Kurt Rasmussen and our CMO Aaron Koenig MD discussing our groundbreaking work with our lead #neuroplastogen, DLX-001, and how Delix is pioneering innovative new treatments for #neuropsychiatric conditions that deliver therapeutic benefits without causing hallucinogenic or cardiotoxic effects. 

Check out the full article: https://lnkd.in/eaWzGF7h.

In a recent article, POLITICO highlighted the United States Department of Defense grant awarded to Delix Therapeutics to support the ongoing development of our novel, non-hallucinogenic #neuroplastogen designed to safely repair and restore hearing loss for both military personnel and civilians.

Read the full piece here: https://lnkd.in/gBNWBGAw.

June is #AlzheimersandBrainAwarenessMonth, an important time to raise awareness of the significance of #brainhealth. 

At Delix Therapeutics, we're developing first-in-class #neuroplastogens that promote the brain's innate ability to repair itself, and in doing so, pioneering a new era in #CNS disease treatment.

Learn more about our science here: https://lnkd.in/eCRnJMv5.

Metric
Company Name	Delix Therapeutics
Symbol
MSH ID	COM:DELIXTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	delixtherapeutics.com
LinkedIn	delix-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

DELI

COM:DELIXTHERAPEUTICS

Delix Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue